A Phase 2 interventional study of KU-0059436 (AZD2281)(PARP inhibitor) and KU-0059436 (AZD2281)(PARP inhibitor) in Ovarian Neoplasm, sponsored by AstraZeneca. Completed at 11 sites in 5 countries. Open to female participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2018-08-01.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies testing olaparib in Ovarian Neoplasms — 13 open to participants now, 26 under way, 9 of them phase 3. olaparib · Ovarian Neoplasms.
Among the 69 studies testing olaparib in Ovarian Neoplasms, this one is the 40th largest by enrollment, is one of 2 that started in 2007, is one of 32 in phase 2, and was the 1st registered.
3,390 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.
Browse Ovarian Neoplasms studies →13 of the 69 studies testing olaparib in Ovarian Neoplasms are open now, in 8 countries. Recruiting first, the newest first:
Bai-Rong Xia · Sites in China
Ages 18–75 · Women only
Daewoong Pharmaceutical Co. LTD. · Sites in Korea, Republic of
Ages 19+ · Women only
Boryung Pharmaceutical Co., Ltd · Sites in Korea, Republic of
Ages 19–74 · Women only
The Netherlands Cancer Institute · Sites in Netherlands
Ages 18–100 · Women only
NRG Oncology · Sites in United States, Japan, Puerto Rico
Ages 18+
By country, each count listing its studies:
olaparib: first FDA approval 2014 (LYNPARZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 602 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.
This study: 18 Years to 130 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, olaparib is the treatment under test here. Read study by study →
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 35 · Phase 3 17 · Phase 4 3
First in 2005; this study’s year is marked. 2 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 58 is close to the median of 54 across 2,556 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 96 across the 69 interventional studies. Of the 33 that completed or were terminated, 16 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 69 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
70 studies in Ovarian Neoplasms by AstraZeneca: 8 open now, 20 under way, 6 of them phase 3. Of 45 finished, 15 (33%) have results posted.
Among the 70 studies in Ovarian Neoplasms by AstraZeneca, this one is the 35th largest by enrollment of the 47 interventional ones that give a count, is one of 3 that started in 2007, is one of 12 in phase 2, and was the 3rd registered.
AstraZeneca’s Ovarian Neoplasms studies by the year they started, since 2001.
5 of the studies testing olaparib in Ovarian Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04421963Phase 3AstraZenecaRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib | 2027-04-06 |
| NCT03579316M.D. Anderson Cancer CenterAdavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | 2026-12-31 |
| NCT07371104Daewoong Pharmaceutical Co. LTD.Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer | 2027-03 |
| NCT07460180The Netherlands Cancer InstituteThe PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cytoreductive Surgery and HIPEC in Ovarian Cancer | 2027-05-01 |
| NCT03943173M.D. Anderson Cancer CenterOlaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery | 2027-06-27 |
Add all 5 to your calendar (.ics) → With an account.
Among the 69 studies testing olaparib in Ovarian Neoplasms, from their registry updates:
Among AstraZeneca’s 70 in Ovarian Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to see if the drug KU 0059436 is effective and well tolerated in treating patients with measurable BRCA1- or BRCA2-positive advanced ovarian cancer and for whom no curative therapeutic option exists.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: KU-0059436 (AZD2281)(PARP inhibitor)
Drug: KU-0059436 (AZD2281)(PARP inhibitor)
oral
Also known as: Olaparib
oral
Confirmed Objective Tumour Response (According to Response Evaluation Criteria In Solid Tumors (RECIST)
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT/MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease from baseline in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Time frame: Baseline, every 8 also at study termination or initiation of confounding anti-cancer therapy.
Clinical Benefit (CB)
Clinical Benefit (CB) is defined as the percentage of patients with a RECIST tumour response of confirmed complete response, partial response or stable disease for ≥8 weeks)
Time frame: End of study
Duration of Response
Duration of response to olaparib
Time frame: End of study
Best Percentage Change in Tumour Size
The best % change (reduction) from baseline in tumour size (defined as the sum of the longest diameters as measured among all target lesions).
Time frame: End of study
Progression-Free Survival (PFS)
Progression-Free Survival (PFS) is defined as the time from first dose to the earlier date of radiologic progression (as per RECIST criteria) or death by any cause in the absence of objective progression.
Time frame: End of study
The first patient was enrolled on June 11, 2007 and efficacy and safety data were collected up to the data cut-off of March 17, 2009. Patients were enrolled at 12 centres in 5 countries: Australia, Germany, Spain, Sweden and the USA.
| Milestone | Olaparib 100 mg bd | Olaparib 400 mg bd |
|---|---|---|
| Started | 24 | 33 |
| Completed | 7 | 17 |
| Not completed | 17 | 16 |
| Withdrew: Death | 1 | 1 |
| Withdrew: Lack of efficacy | 16 | 10 |
| Withdrew: Adverse event | 0 | 2 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Non-compliance | 0 | 1 |
| Withdrew: Intercurrent illness | 0 | 1 |
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT/MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease from baseline in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
| Participants | Olaparib 100 mg bd | Olaparib 400 mg bd |
|---|---|---|
| PP Analysis Set | 3 | 11 |
| ITT Analysis Set | 3 | 11 |
Clinical Benefit (CB) is defined as the percentage of patients with a RECIST tumour response of confirmed complete response, partial response or stable disease for ≥8 weeks)
| Percentage of participants | Olaparib 100 mg bd | Olaparib 400 mg bd |
|---|---|---|
| Clinical Benefit (CB) | 45.5 (26.9 to 65.3) | 71.0 (53.4 to 83.9) |
Duration of response to olaparib
| Days | Olaparib 100 mg bd | Olaparib 400 mg bd |
|---|---|---|
| Duration of Response | 242 (169 to 288) | 301 (126 to 506) |
The best % change (reduction) from baseline in tumour size (defined as the sum of the longest diameters as measured among all target lesions).
| Percent change | Olaparib 100 mg bd | Olaparib 400 mg bd |
|---|---|---|
| Best Percentage Change in Tumour Size | -5.1 (-85.7 to 66.1) | -25.8 (-100.0 to 150.0) |
Progression-Free Survival (PFS) is defined as the time from first dose to the earlier date of radiologic progression (as per RECIST criteria) or death by any cause in the absence of objective progression.
| Days | Olaparib 100 mg bd | Olaparib 400 mg bd |
|---|---|---|
| Progression-Free Survival (PFS) | 62.5 (56 to 113) | 226 (105 to 338) |
Collected over From baseline, every visit until 30 days after last dose.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Olaparib 100 mg bd | 10/24 (41.7%) | 7/24 (29.2%) | 23/24 (95.8%) |
| Olaparib 400 mg bd | 11/33 (33.3%) | 12/33 (36.4%) | 33/33 (100%) |
| Event | Olaparib 100 mg bd | Olaparib 400 mg bd |
|---|---|---|
| Intestinal ObstructionGastrointestinal disorders | 0/24 | 2/33 |
| NauseaGastrointestinal disorders | 1/24 | 2/33 |
| VomitingGastrointestinal disorders | 1/24 | 2/33 |
| NeutropeniaBlood and lymphatic system disorders | 1/24 | 1/33 |
| Cardiac Failure CongestiveCardiac disorders | 1/24 | 0/33 |
| Abdominal PainGastrointestinal disorders | 1/24 | 0/33 |
| Large Intestinal ObstructionGastrointestinal disorders | 1/24 | 1/33 |
| Blood Pressure IncreasedInjury, poisoning and procedural complications | 1/24 | 0/33 |
| HyponatraemiaMetabolism and nutrition disorders | 1/24 | 0/33 |
| EncephalopathyNervous system disorders | 1/24 | 0/33 |
| Event | Olaparib 100 mg bd | Olaparib 400 mg bd |
|---|---|---|
| NauseaGastrointestinal disorders | 15/24 | 21/33 |
| FatigueGeneral disorders | 13/24 | 17/33 |
| DiarrhoeaGastrointestinal disorders | 7/24 | 12/33 |
| VomitingGastrointestinal disorders | 6/24 | 11/33 |
| Abdominal PainGastrointestinal disorders | 4/24 | 9/33 |
| ConstipationGastrointestinal disorders | 6/24 | 4/33 |
| AnaemiaBlood and lymphatic system disorders | 3/24 | 7/33 |
| HeadacheNervous system disorders | 4/24 | 7/33 |
| Urinary Tract InfectionInfections and infestations | 5/24 | 2/33 |
| RashSkin and subcutaneous tissue disorders | 5/24 | 5/33 |
| Age, Continuous(Years) | Olaparib 100 mg bd | Olaparib 400 mg bd | Total |
|---|---|---|---|
| Mean | 55.6 ± 8.02 | 56.8 ± 10.49 | 56 ± 9 |
| Sex: Female, Male(Participants) | Olaparib 100 mg bd | Olaparib 400 mg bd | Total |
|---|---|---|---|
| Female | 24 | 33 | 57 |
| Male | 0 | 0 | 0 |
| BRCA mutation(Participants) | Olaparib 100 mg bd | Olaparib 400 mg bd | Total |
|---|---|---|---|
| BRCA1 | 19 | 21 | 40 |
| BRCA2 | 5 | 12 | 17 |
Ran from Jun 2007 to primary completion in Mar 2009, 21 months.
Results were first posted in Jan 2015, 5 years 10 months after primary completion. A results delay was requested in Sep 2013.
Of 116 industry-sponsored phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 51. This study's 21 months is below that.
Counting every sponsor, half of 344 studies reached it within 47 months; a quarter within 33 and three quarters within 72.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olaparib